Jazz Pharmaceuticals Plc - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jazz Pharmaceuticals, Inc. on March 9, 2011. The report discloses a change in the company's executive leadership regarding the appointment of a Principal Accounting Officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
Effective March 9, 2011, the Company appointed Karen J. Wilson, previously its Vice President of Finance, to serve as its Principal Accounting Officer. Consequently, Joan E. Colligan will no longer serve in that capacity. Ms. Wilson joined the Company in February 2011 from PDL BioPharma, Inc., where she served as Vice President of Finance and Principal Accounting Officer since 2009.
Management Commentary, Risks, and Unusual Items
In connection with her appointment, Ms. Wilson entered into the Company's Amended and Restated Executive Change in Control and Severance Benefit Plan. Under this plan, she is entitled to severance benefits if her employment is terminated without cause or constructively within 12 months following a change in control. Benefits include a lump sum cash payment (generally 12 months of salary and bonus), full COBRA premium coverage for up to 12 months, and full acceleration of vesting for outstanding options and equity awards. Additionally, Ms. Wilson signed the Company's standard indemnity agreement.
Investor Verification Checklist
- Verify the effective date of Karen J. Wilson's appointment as Principal Accounting Officer (March 9, 2011).
- Confirm the departure of Joan E. Colligan from the Principal Accounting Officer role.
- Review the specific terms of the Severance Benefit Plan and Indemnity Agreement filed as exhibits to prior SEC filings.
- Assess the impact of this leadership change on the company's financial reporting processes.